Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof

Inventors: Ronnie Rong Wei (Weston, MA); Ling Xu (Newton Center, MA); Zhi-Yong Yang (Newton Center, MA); Edward Seung (Medford, MA); Gary J. Nabel (Delray Beach, FL)

Assignee: ModeX Therapeutics, Inc.

C07K16/468 A61P31/12 A61P35/00 C07K16/082 C07K16/087 C07K16/1009 C07K16/1018 C07K16/1027 C07K16/1063 C07K16/1081 C07K16/125 C07K16/1253 C07K16/1275 C07K16/1285 C07K16/2803 C07K16/2809 C07K16/2818 C07K16/2866 C07K16/2878 C07K16/2887 C07K16/3076 C07K19/00 C07K2317/21 C07K2317/24 C07K2317/31 C07K2317/73 C07K2317/92 C07K2319/41 C07K2319/42 C07K2319/43

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12668645
App. No.: 17/936,047
Granted: Jun 30, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells; chimeric antigen receptors (CARs); immune cells; pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

Claims (29)

1 . A polypeptide having at least 95% identity to any one of SEQ ID NOs: 30 and 32-43; wherein the polypeptide comprises the sequences of:

(i) a heavy chain complementarity determining region (CDR) 1 comprising the sequence of SEQ ID NO: 64; a heavy chain CDR2 comprising the sequence of SEQ ID NO: 65; a heavy chain CDR3 comprising the sequence of SEQ ID NO: 66; a light chain CDR1 comprising the sequence of SEQ ID NO: 67; a light chain CDR2 comprising the sequence of SEQ ID NO: 68; and a light chain CDR3 comprising the sequence of SEQ ID NO: 69;

(ii) a heavy chain CDR1 comprising the sequence of SEQ ID NO: 82; a heavy chain CDR2 comprising the sequence of SEQ ID NO: 83; a heavy chain CDR3 comprising the sequence of SEQ ID NO: 84; a light chain CDR1 comprising the sequence of SEQ ID NO: 85; a light chain CDR2 comprising the sequence of SEQ ID NO: 86; and a light chain CDR3 comprising the sequence of SEQ ID NO: 87; and

(iii) a heavy chain CDR1 comprising the sequence of SEQ ID NO: 88; a heavy chain CDR2 comprising the sequence of SEQ ID NO: 89; a heavy chain CDR3 comprising the sequence of SEQ ID NO: 90; a light chain CDR1 comprising the sequence of SEQ ID NO: 91; a light chain CDR2 comprising the sequence of SEQ ID NO: 92; and a light chain CDR3 comprising the sequence of SEQ ID NO: 93.

2 . The polypeptide of claim 1 , having at least 97% identity to any one of SEQ ID NOs: 30 and 32-43.

3 . The polypeptide of claim 2 , having the sequence of any one of SEQ ID NOs: 30 and 32-43.

4 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO:30.

5 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO:32.

6 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 33.

7 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 34.

8 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 35.

9 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 36.

10 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 37.

11 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 38.

12 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 39.

13 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 40.

14 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 41.

15 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 42.

16 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 43.

17 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 30.

18 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 32.

19 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 33.

20 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 37.

21 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 38.

22 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 39.

23 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 40.

24 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 41.

25 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 42.

26 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 43.